...
首页> 外文期刊>Clinical neurology and neurosurgery >Impact of antithrombotic treatment on clinical outcomes after craniotomy for unruptured intracranial aneurysm
【24h】

Impact of antithrombotic treatment on clinical outcomes after craniotomy for unruptured intracranial aneurysm

机译:抗血栓形成对颅内动脉瘤颅内动脉瘤Craniot术后临床结果的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Highlights ? Outcomes after craniotomy does not depend on perioperative antithrombotic treatment. ? Intracranial hemorrhage correlates with perioperative antithrombotic treatment. ? Morbidity associates with posterior location of the aneurysm and surgical procedure. Abstract Objective Patients receiving antithrombotic treatment occasionally undergo craniotomy. We aimed to explore the impact of perioperative use of antithrombotic agents on the occurrence of surgical complications and clinical outcomes in patients with unruptured intracranial aneurysm (UIA). Patients and methods We retrospectively analyzed 401 consecutive patients who had undergone craniotomy for UIA at our institution between January 2006 and December 2016. Patients were divided into two groups: those who received oral antiplatelet and/or anticoagulant agents during the perioperative period (antithrombotic treatment group, n = 45); and those who did not (no antithrombotic treatment group, n = 356). In the antithrombotic treatment group, 40 patients received antiplatelet alone, 2 received anticoagulant alone, and 3 received antiplatelet plus anticoagulant. Results The two groups showed no significant differences in mortality, morbidity, or occurrence of symptomatic brain infarction, but intracranial hemorrhage was more frequent in the antithrombotic treatment group than in the no antithrombotic treatment group (p = 0.0187). Multivariate analysis revealed posterior location of the aneurysm (odds ratio (OR), 8.10; 95% confidence interval (CI), 2.77-23.68; p = 0.0001) and surgical procedure (OR, 5.48; 95%CI, 1.68-17.86; p = 0.0048) as significantly correlated with severe morbidity, and intracranial hemorrhage as correlated significantly with antithrombotic treatment (OR, 3.83; 95%CI, 1.36-10.76; p = 0.0110). Conclusions This study provides important information about the occurrence of intracranial hemorrhage and clinical outcomes in patients undergoing antithrombotic treatment during the perioperative period of craniotomy for UIA.
机译:强调 ?结石术后的结果不依赖于围手术期抗血栓形成治疗。还颅内出血与围手术期抗血栓处理相关。还发病率与动脉瘤和外科手术的后勤相关联。摘要目的患者接受抗血栓治疗偶尔接受开颅术。我们的目标是探讨近术使用抗血栓药物对颅内动脉瘤(UIA)患者手术并发症和临床结果的影响。患者和方法我们回顾性分析了401名连续2006年1月至2016年12月在我们的机构内部对UIA开颅术的连续患者。患者分为两组:在围手术期间接受口服抗血小板和/或抗凝血剂的人(抗血栓治疗组,n = 45);和那些没有(没有抗血栓治疗组,n = 356)的人。在抗血栓形成组中,40名患者接受抗血小板,仅2次抗凝血剂,3次接受抗血管涂层加抗凝血剂。结果两组表明,症状性脑梗塞的死亡率,发病率或发生的显着差异,但在抗血栓处理组中更频繁地常见于抗血栓处理组(P = 0.0187)。多变量分析显示动脉瘤的后部位置(差距比(或),8.10; 95%置信区间(CI),2.77-23.68; p = 0.0001)和外科手术(或5.48; 95%CI,1.68-17.86; p = 0.0048)与严重的发病率显着相关,与抗血栓处理显着相关的颅内出血(或3.83; 95%CI,1.36-10.76; P = 0.0110)。结论本研究提供了关于在UIA的围手术期间围手术期间抗血栓治疗患者颅内出血和临床结果的重要信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号